GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2007

BioLineRx In-Licenses Treatment for Acute Kidney Injury

  • BioLineRx signed a worldwide, exclusive license agreement with Gene Vector Technologies for the development and commercialization of BL-4040, a drug for the treatment of acute kidney injury (AKI).

    BL-4040 is a genetically engineered version of the major capsid protein VP1, derived from the outer protein shell of the virus SV40. By boosting the natural stress response and survival pathways of kidney cells, BL-4040 may prevent apoptosis of kidney cells following AKI, the companies explain.

    “BL-4040 is extremely effective in mice, relatively simple to produce, and nontoxic even at very high doses,” says Morris C. Laster, M.D., CEO of BioLineRx. “We believe that BL-4040 offers the potential for a highly effective and safe therapy that taps into the natural defense systems of the body.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?